Table III.
Correlation between BRCA1 promoter methylation and clinicopathological features of sporadic EOC patients.
| BRCA1 methylation, n (%) | ||||
|---|---|---|---|---|
|
|
||||
| Clinicopathological features | n | Positive [50 (35.2)] | Negative [92 (64.8)] | P-valuea |
| Age at diagnosis (years) | 138 | |||
| ≤53 | 79 | 26 (32.9) | 53 (67.1) | 0.742 |
| >53 | 59 | 21 (35.6) | 38 (64.4) | |
| Menopause state | 130 | |||
| Pre-menopause | 45 | 13 (28.9) | 32 (71.1) | 0.318 |
| Post-menopause | 85 | 32 (37.6) | 53 (62.4) | |
| Tumor size (cm) | 119 | |||
| ≤5.0 | 15 | 5 (33.3) | 10 (66.7) | 0.282 |
| 5–10 | 53 | 15 (28.3) | 38 (71.7) | |
| >10 | 51 | 22 (43.1) | 29 (56.9) | |
| Node metastasis | 116 | |||
| No | 89 | 31 (34.8) | 58 (65.2) | 0.834 |
| Yes | 27 | 10 (37.0) | 17 (63.0) | |
| FIGO stage | 127 | |||
| I–II | 31 | 7 (22.6) | 24 (77.4) | 0.085 |
| III–IV | 96 | 38 (39.6) | 58 (60.4) | |
| Histological type | 130 | |||
| Serous | 110 | 38 (34.5) | 72 (65.5) | 0.506 |
| Mucinous | 12 | 2 (16.7) | 10 (83.3) | |
| Clear cell | 8 | 3 (37.5) | 5 (62.5) | |
| Tumor location | 129 | |||
| Single side | 56 | 11 (19.6) | 45 (80.4) | 0.015 |
| Both sides | 73 | 29 (39.7) | 44 (60.3) | |
| CA-125 (U/ml) | 89 | |||
| 35–500 | 40 | 9 (22.5) | 31 (77.5) | 0.013 |
| 500–1000 | 32 | 18 (56.2) | 14 (43.8) | |
| >1000 | 17 | 7 (41.2) | 10 (58.8) | |
| CA19-9 (U/ml) | 88 | |||
| 0–37 | 67 | 24 (35.8) | 43 (64.2) | 0.083 |
| >37 | 21 | 12 (57.1) | 9 (42.9) | |
| CEA (U/ml) | 79 | |||
| 0–5 | 72 | 20 (27.8) | 52 (72.2) | 0.191 |
| >5 | 7 | 4 (57.1) | 3 (42.9) | |
a
Obtained from Pearson’s χ2 or Fisher’s exact test.
BRCA1, breast cancer susceptibility gene 1; EOC, epithelial ovarian carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.